CureVac (NASDAQ:CVAC) Shares Up 7.7% - Still a Buy?

CureVac (NASDAQ:CVAC - Get Free Report)'s stock price was up 7.7% during mid-day trading on Monday . The company traded as high as $3.59 and last traded at $3.48. Approximately 269,297 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 797,755 shares. The stock had previously closed at $3.23.Analyst Ratings Changes2 Small-Cap Stocks Set to Shine in a Bull MarketSeparately, JMP Securities reiterated a "market outperform" rating and set a $16.00 price target on shares of CureVac in a report on Friday, February 14th.Get Our Latest Analysis on CVACCureVac Trading Up 5.7 %3 Stocks to Buy For the COVID Resurgence The business has a 50 day simple moving average of $3.04 and a two-hundred day simple moving average of $3.18. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The company has a market cap of $766.11 million, a PE ratio of 6.21 and a beta of 2.48. CureVac (NASDAQ:CVAC - Get Free Report) last posted its quarterly earnings results on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $15.44 million during the quarter, compared to analysts' expectations of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, analysts forecast that CureVac will post 0.72 EPS for the current fiscal year. Institutional Inflows and OutflowsA number of hedge funds and other institutional investors have recently added to or reduced their stakes in CVAC. BNP Paribas Financial Markets acquired a new position in shares of CureVac during the fourth quarter worth about $585,000. Two Sigma Investments LP purchased a new stake in CureVac during the 4th quarter worth approximately $391,000. Alyeska Investment Group L.P. boosted its stake in shares of CureVac by 25.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock valued at $1,705,000 after buying an additional 100,000 shares during the last quarter. Jane Street Group LLC grew its position in shares of CureVac by 239.0% during the third quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after buying an additional 55,867 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in CureVac by 98.1% in the fourth quarter. Northern Trust Corp now owns 60,100 shares of the company's stock valued at $205,000 after acquiring an additional 29,759 shares in the last quarter. Institutional investors and hedge funds own 17.26% of the company's stock. About CureVac (Get Free Report)CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.Featured StoriesFive stocks we like better than CureVacUpcoming IPO Stock Lockup Period, ExplainedBest Defense Stocks in 2025... So FarHow to Use Stock Screeners to Find StocksAlphabet Rebounds After Strong Earnings and Buyback AnnouncementInvesting In Preferred Stock vs. Common StockCould Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in CureVac Right Now?Before you consider CureVac, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.While CureVac currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here